New River reiterated at buy by Merrill

New River Pharmaceuticals Inc. was reiterated by Merrill Lynch analyst David Munno at buy. Merrill believes the stock's recent weakness is a buying opportunity, with New River being one of the analyst's top biotech stocks for 2006. NRP104 is worth $20 to $24 in a worst-case scenario, according to Merrill. The analyst also believes the commercial potential of NRP104 for ADHD is not tied to scheduling. Shares of the Radford, Va., specialty pharmaceutical company were down 9 cents, or 0.34%, at $26.40 on volume of 511,510 shares versus the three-month running average of 236,229 shares. (Nasdaq: BLUD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.